| Literature DB >> 34876828 |
Preeyachat Limtong1, Poonkiat Suchonwanit1, Kumutnart Chanprapaph1, Suthinee Rutnin1.
Abstract
BACKGROUND: Erythema nodosum (EN) is the most common panniculitis associated with a wide variety of conditions. Updated studies regarding the clinicopathological manifestations related to etiologies of EN and its prognosis are limited.Entities:
Keywords: leg nodules; panniculitis; septal panniculitis; subcutaneous mass; subcutaneous nodule
Year: 2021 PMID: 34876828 PMCID: PMC8643131 DOI: 10.2147/CCID.S343351
Source DB: PubMed Journal: Clin Cosmet Investig Dermatol ISSN: 1178-7015
Figure 1Histopathology of erythema nodosum; (A) Septal panniculitis without vasculitis (Hematoxylin-eosin stain, x40). (B) Higher magnification demonstrating septal fibrosis with lymphohistiocytic infiltration (Hematoxylin-eosin stain, x100).
Diagnostic Criteria for Diseases and Conditions Associated with Secondary Erythema Nodosum
| Diseases | Criteria for Diagnosis |
|---|---|
| Presence of a positive culture result or a positive nucleic acid amplification test or acid-fast bacilli found in the specimen from the site of infection | |
| Latent tuberculosis infection (LTBI) | Positive result of either the TST or IGRA without clinical symptoms of active TB infection |
| Disseminated tuberculosis infection | Presence of evidence of hematogenous spreading of tubercle bacilli |
| Nontuberculous mycobacteria (NTM) infection | Consistent of clinical status, radiologic result, and repeated isolation of NTM by positive culture or nucleic acid amplification test from clinical specimens (sputum, biopsy specimens, or blood) |
| Streptococcal infection | Presence of the history of sore throat within the last 3 weeks with a positive throat swab culture or a positive rapid antigen detection test or high level of ASO |
| Considered as the cause of EN if concomitant presence of EN and positive hemoculture result and negative tissue culture result of the pathogen from the EN lesion | |
| Cytomegalovirus (CMV) infection | CMV as isolated or detected from the clinical specimen |
| Human immunodeficiency virus (HIV) infection | Presence of demonstrable antibodies to HIV and/or HIV or one of its components was detected directly from blood specimen |
| Mumps | Compatible clinical symptoms together with positive serological result |
| Disseminated candidiasis | Presence of evidences demonstrating tissue invasion by |
| Behçet’s disease (BD) | Present of symptoms as the 1990 ISG criteria for BD |
| Hematologic malignancies | The diagnoses of myeloid, lymphoid, and myeloproliferative neoplasms were based on WHO classification and cytogenetic abnormalities. |
| Sarcoidosis | Compatible clinical features, radiological results and histopathological results of noncaseating granuloma in the absence of other alternative causes of the granuloma |
| Drug-induced EN | Established temporal correlation with the possible causative drugs, which contained the history of medication taken before the patient developed EN and improvement of lesions after ceasing the drug, in the absence of other precipitating causes |
Abbreviations: ASO, anti-streptolysin-O antibody; BD, Behçet’s disease; CMV, Cytomegalovirus; EN, erythema nodosum; HIV, human immunodeficiency virus; ICBD, International Criteria for Behçet’s disease; IGRA, interferon-gamma release assay; ISG, International Study Group; LTBI, latent Mycobacterium tuberculosis infection; NTM, Nontuberculous mycobacteria; TB, tuberculosis; TST, tuberculin skin test; WHO, World Health Organization.
Figure 2Recruitment process and the study flow diagram.
Demographic Data, Clinicopathological Results of Erythema Nodosum
| - Mean age at diagnosis (years [± SD]) | 40.6 ± 17.3 |
| - Sex; N (%) | |
| Male | 25 (14.8%) |
| Female | 144 (85.2%) |
| - Median onset of EN (months [IQR]) | 1 (0.3–3) |
| - Median follow-up duration (months [IQR]) | 2.3 (0.7–7.5) |
| - Recurrence | 55/118 (46.6%) |
| - Median time of recurrence (months [IQR]) | 3 (1–5.5) |
| - Asymptomatic | 17/165 (10.3%) |
| - Tenderness | 142/165 (86.1%) |
| - Pruritus | 2/165 (1.2%) |
| - Tenderness and pruritus | 4/165 (2.4%) |
| - Nodules | 128 (75.7%) |
| - Plaques | 52 (30.8%) |
| - Papules | 13 (7.7%) |
| - Patches | 7 (4.1%) |
| - Macules | 4 (2.4%) |
| - Cellulitis-like lesion | 1 (0.6%) |
| - Red | 134 (87.6%) |
| - Brown | 33 (21.6%) |
| - Purple | 9 (5.9%) |
| - Skin-color | 5 (3.3%) |
| - Gray | 2 (1.3%) |
| - Lower extremities | 159/168 (94.6%) |
| - Upper extremities | 39/168 (23.2%) |
| - Trunk | 11/168 (6.5%) |
| - Face and neck | 6/168 (3.6%) |
| - Acute EN | 52 (30.8%) |
| - Chronic EN | 117 (69.2%) |
Abbreviations: EN, erythema nodosum; IQR, interquartile range; SD, standard deviation.
Etiologies of Erythema Nodosum
| ● Bacterial infections | 24 (38.1%) |
| o Mycobacterium tuberculosis | 15 (62.5%) |
| -TB lymphadenitis | 7 (46.7%) |
| -Pulmonary TB | 5 (33.3%) |
| -Latent TB infection | 2 (13.3%) |
| -Disseminated TB | 1 (6.7%) |
| o Streptococcal infection | 4 (16.7%) |
| o Pseudomonas infection | 4 (16.7%) |
| o Nontuberculous mycobacterium infection | 1 (4.1%) |
| ● Viral infections | |
| o CMV | 3 (4.8%) |
| o HIV | 1 (33.3%) |
| o Mumps | 1 (33.3%) |
| ● Fungal infection | 1 (33.3%) |
| o Disseminated candidiasis | 1 (1.6%) |
| ● Drugs | 15 (23.8%) |
| o Oral contraceptive pills | 13 (86.7%) |
| o Others (G-CSF, Vemurafenib) | 2 (13.3%) |
| ● Hematologic malignancies | 9 (14.3%) |
| o AML | 4 (44.4%) |
| o DLBCL | 3 (33.3%) |
| o CLL | 1 (11.1%) |
| o Primary myelofibrosis | 1(11.1%) |
| ● Behcet’s disease | 5 (7.9%) |
| ● Pregnancy | 4 (6.3%) |
| ● Lung cancer | 1 (1.6%) |
| ● Sarcoidosis | 1 (1.6%) |
Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus; DLBCL, diffuse large B-cell lymphoma; EN, erythema nodosum; G-CSF, granulocyte colony-stimulating factor; HIV, human immunodeficiency virus; IQR, interquartile range; SD, standard deviation; TB, tuberculosis.
Treatment of Erythema Nodosum
| Categories | Idiopathic EN (N = 106) | Secondary EN (N = 63) |
|---|---|---|
| Systemic treatment | ||
| - Yes | 99/106 (93.4%) | Yes 44/63 (69.8%) |
| - No | 7/106 (6.6%) | No 19/63 (30.2%) |
| Median duration to resolution (weeks [IQR]) | ||
| - After initiation of treatment | 5 (3–10) | 4(2–6) |
| - Spontaneous resolution without treatment | 3.5 (1.5–4) | 4 |
| -Colchicine | 83/99 (83.8%) | 35/44 (79.6%) |
| -NSAIDs | 74/99 (74.8%) | 31/44 (70.5%) |
| o Indomethacin | 69/74 (93.2%) | 24/31 (77.4%) |
| o Naproxen | 4/74 (5.4%) | 6/31 (19.4%) |
| o Diclofenac | 1/74 (1.4%) | 0/31 (0%) |
| o Ibuprofen | 0/74 (0%) | 1/31 (3.2%) |
| -SSKI | 19/99 (19.2%) | 10/44 (22.7%) |
| -ASA | 3/99(3.0%) | 0/44 (0%) |
| -HCQ | 1/99 (1.0%) | 1/44 (2.3%) |
Abbreviations: ASA, acetylsalicylic acid; EN, erythema nodosum; HCQ, hydroxychloroquine; IQR, interquartile range; NSAIDs, non-steroidal anti-inflammatory drugs; SD, standard deviation; SSKI, saturated solution of potassium iodide.
Figure 3Erythema nodosum at the dorsum of the left hand in a patient diagnosed with acute myeloid leukemia.
Figure 4Histopathology of primary erythema nodosum; (A) Septal panniculitis with focal peripheral lobular infiltration (Hematoxylin-eosin stain, x40). (B) Higher magnification demonstrating numerous eosinophils in the area of focal peripheral lobular panniculitis (Hematoxylin-eosin stain, x400).
Clinicopathological Findings and Investigations in Relations to Secondary Erythema Nodosum
| Factors | Logistic Regression Analysis | ||
|---|---|---|---|
| OR | 95% CI | p-value | |
| - Presence of lesions on upper extremities | 2.42 | [1.17, 5.01] | 0.018* |
| - Fever | 3.33 | [1.52, 7.30] | 0.003* |
| - Cough | 7.12 | [0.78, 65.18] | 0.082 |
| - Arthralgia | 2.28 | [0.89, 5.85] | 0.087 |
| - Lymphadenopathy | 20.8 | [3.12, -]a | <0.001* |
| - Presence of focal peripheral lobular panniculitis | 1.93 | [1.01, 3.65] | 0.045* |
| - Presence of focal peripheral lobular panniculitis with eosinophils | 0.32 | [0.11, 0.90] | 0.030* |
| - Chronic EN | 0.83 | [0.42, 1.62] | 0.578 |
Notes: *Statistically significant. aCannot demonstrate the upper value of 95% confidence interval from the exact logistic regression analysis due to the value of approaching infinity.
Abbreviations: CI, confidence interval; EN, erythema nodosum; OR, odds ratio.